Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for more than 4 Months (VICI): A Randomised, Double-blind, Placebo-controlled Trial
The VICI trial is highly topical. Dr Narme Deva, Consultant Ophthalmologist & Honorary Senior Lecturer at the University of Auckland, explores the Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. She explains the results are unequivocal and based on a robust trial of 114 patients. Eplerenone does not improve BCVA in people with chronic CSCR after 12 months of treatment. As ever, Dr Deva reminds listeners that evidence-based medicine includes using reliable data to make decisions, even when patients and ophthalmologists are faced with limited treatment options to prevent vision loss.
View article here
Popular Podcasts
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.